Results 51 to 60 of about 4,155 (158)

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials

Rheumatology and Therapy
Introduction The human leukocyte antigen (HLA)-B27 is associated with axial spondyloarthritis (axSpA) and is a predictor of response to tumor necrosis factor inhibitors. However, limited data are available on HLA-B27 and interleukin-17 inhibitors.
John D. Reveille, Martin Rudwaleit, Proton Rahman, Jose A. Maldonado-Cocco, Marina Magrey, Rebecca Bolce, Khai Jing Ng, Theresa Hunter Gibble, Jeffrey Lisse, So Young Park, Andris Kronbergs, Victoria Navarro-Compán   +11 more
doaj   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Early Detection of Inflammatory Bowel Disease in Patients with Axial Spondyloarthritis [PDF]

Al-Azhar International Medical Journal
Background: Spondyloarthritis (SpA) is a collection of rheumatic diseases that are characterized by inflammation that shares common serologic, radiologic and clinical characteristics.
Ibrahim Elsakka, Ali Ali, Hassan Awad, Mamdouh Khairy   +3 more
doaj   +1 more source

Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Aim To describe Australian trends in JAKi uptake, where there are no restrictions on the sequence of their use in clinical practice. Methods We included all people aged 18 years and over initiating a JAKi between 1 October 2015 and 31 August 2022.
Claire T. Deakin, Michael O. Falster, Geoffrey O. Littlejohn, Peter Youssef, David Liew, Nicole L. Pratt, Sallie‐Anne Pearson   +6 more
wiley   +1 more source

Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort

RMD Open
Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms as a key element.
Xenofon Baraliakos, Joachim Sieper, Denis Poddubnyy, Martin Rudwaleit, Imke Redeker, Hildrun Haibel, Fabian Proft, Mikhail Protopopov, Valeria Rios Rodriguez, Murat Torgutalp, David Kiefer, Judith Rademacher   +11 more
doaj   +1 more source

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2102-2109, October 2026.
Objective To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0–3) and Short Form‐36 PF subscale (SF‐36, 0–100); radiographic joint damage was measured ...
Pankti Mehta, Shangyi Gao, Virginia Carrizo Abarza, Fadi Kharouf, Daniel Pereira, Richard J. Cook, Dafna D. Gladman, Vinod Chandran, Denis Poddubnyy   +8 more
wiley   +1 more source

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland [PDF]

Rheumatology and Therapy, 2018
The aim of this study is to assess the cost-effectiveness of golimumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) vs. conventional therapy and other tumor necrosis factor inhibitors from the Scottish payer perspective.A model comprising a short-term decision tree and a long-term Markov model was developed to compare cost ...
Rebekah H, Borse, Sumesh, Kachroo, Chloe, Brown, Eilish, McCann, Ralph P, Insinga   +4 more
openaire   +2 more sources

Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro‐Osteitis Disease Activity From a Phase 3 Brodalumab Trial

The Journal of Dermatology, Volume 53, Issue 10, Page 1448-1456, October 2026.
ABSTRACT Pustulotic arthro‐osteitis (PAO) is a clinically important osteoarticular comorbidity affecting approximately 9%–28% of patients with palmoplantar pustulosis (PPP), yet early recognition and standardized activity assessment remain challenging, particularly in routine dermatology practice.
Taiki Nozaki, Manabu Arai, Junko Ochi, Mona Uchida‐Yamada, Masahiro Hashimoto, Mitsuhiro Akiyama, Yuko Kaneko, Yasumasa Kanai, Masahiro Jinzaki   +8 more
wiley   +1 more source

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective We recently reported an immune profile that stratifies patients with axial spondyloarthritis based on clinical response to secukinumab. We now undertake an exploratory study on the secukinumab nonresponder patients to determine if immunologic changes occur during their initial secukinumab treatment that could determine their next biologic ...
Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D. Inman   +4 more
wiley   +1 more source

State-of-the-Art Review on the Treatment of Axial Spondyloarthritis

Medical Sciences
The term axial spondyloarthritis (axSpA) encompasses patients with both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms of the disease. These are two entities within the same family that share many genetic and pathogenic factors, but they ...
Evripidis Kaltsonoudis, Panagiota Karagianni, Tereza Memi, Eleftherios Pelechas   +3 more
doaj   +1 more source